Evidence-based recommendations for the management of acne fulminans and its variants - 14/12/17
, Andrea L. Zaenglein, MD (co-chair) c, d, Hilary E. Baldwin, MD e, Neal Bhatia, MD f, Karen A. Chernoff, MD g, James Q. Del Rosso, DO h, Lawrence F. Eichenfield, MD a, b, Marc H. Levin, MD, PhD i, James J. Leyden, MD j, Diane M. Thiboutot, MD c, d, Guy F. Webster, MD, PhD k, Sheila Fallon Friedlander, MD (co-chair) a, bAbstract |
Background |
Acne fulminans (AF) is a severe variant of inflammatory acne. It typically manifests as an explosive worsening and ulceration of skin lesions, and can be associated with systemic symptoms. However, there is a paucity of evidence-based information and no clear guidelines concerning the classification and treatment of AF.
Objective |
To better define the spectrum of AF and its variants, devise optimal therapeutic approaches, and identify areas of future research.
Methods |
A panel of physicians with expertise in severe acne vulgaris was convened after a comprehensive literature review of severe acne variants. Priority topics were reviewed and presented by each panelist at a 5-hour conference. Following review of the audiotape and scribed notes from the conference, surveys were utilized to address points of controversy and to clarify consensus recommendations.
Results |
Appropriate clinical case presentations and consensus survey questions were utilized to create final recommendations based on both the literature and the expert consensus.
Limitations |
Limited evidenced-based data and prospective studies in the literature concerning the treatment of AF is available.
Conclusion |
These guidelines better characterize AF and provide health care practitioners approaches to the classification, treatment, and prevention of AF and its variants.
Le texte complet de cet article est disponible en PDF.Key words : acne fulminans, diagnosis, isotretinoin, PAPA, PAPASH, pseudotumor cerebri syndrome, SAPHO, treatment
Abbreviations used : AF, AF-SS, AF-WOSS, ICP, IIAF-SS, IIAF-WOSS, IL-1, PAPA, PAPASH, PASH, PTCS, SAPHO
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Previously presented at the American Acne and Rosacea Society Acne Fulminans Consensus Conference, San Francisco, California, March 19, 2015. |
Vol 77 - N° 1
P. 109-117 - juillet 2017 Retour au numéro
Article précédent
- Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age
- Andre Vadimovich Moyakine, Saskia Spillekom-van Koulil, Catharina Joanna Maria van der Vleuten
- Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis
- Amit Garg, Jonathan Lavian, Gloria Lin, Andrew Strunk, Allireza Alloo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?